Haemostat is a type of haemostatic instrument, which is designed to be used during the vascular surgeries to control bleeding, accelerate the clotting process and explore the wound area. It is also used for holding and fixing the superficial fascia during undermining the wounds. A haemostat stops the bleeding condition by absorbing the coagulation issues, tissue bonding and carrying procoagulant factors to the victim’s haemorrhage site.

The key industry growth drivers for haemostats market are the growing ageing population, increasing cardiovascular surgical procedures, evolving personal healthcare expenditure and accelerating economic growth. The market is trending with rising pharmaceuticals research and development (R&D) expenditures and escalating e-commerce pharmaceutical products sales. However, there are some growth hindering factors in the market include stringent regulations and intense competition.

Regionally, the U.S. is expected to hold the leading position in the market, due to surging demand for thrombin and fibrin sealants by the physicians for adhering the patients damaged tissues & sealing the injured blood vessel(s) during operation.

“Global Haemostats Market: Industry Analysis & Outlook (2019-2023)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. Key players i.e. Johnson & Johnson (Ethicon Inc.), Pfizer Inc., Baxter International Inc. and Becton, Dickinson and Company are being profiled along with their respective financials and growth strategies.